A rare aggressive B-cell non-Hodgkin lymphoma characterized by a rearrangement in MYC and BCL2 and/or BCL6 (so-called double-hit or triple-hit lymphoma). The category includes double-hit cases with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma blastoid cases with a double-hit and cases with a DLBCL not otherwise specified morphology with a double-hit. It refers only to de novo cases not to lymphomas with a history of pre-existing or coexistent indolent lymphoma. Patients typically present with widespread disease including involvement of lymph nodes bone marrow and central nervous system.
Data from Orphanet are used to provide information on a disease's name, synonym(s), and overview. Reference: Access aggregated data from Orphanet at Orphadata. Orphadata: Free access data from Orphanet. © INSERM 1999. Available on http://www.orphadata.org. Data version April 2026
Newly diagnosed with
High grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement?
Our RARE Concierge Services Guides are available to assist you by providing information, resources and connections as you navigate your rare disease journey.
Advocacy Organizations
RUNX1 Research Program
At the RUNX1 Research Program, our mission is to improve the quality of life and prevent cancer in patients with RUNX1-FPD. We do this by promoting awareness and funding world-class collaborative research with an empowered patient community.
Don't see your organization here. Let us know here.
Clinical Trials
For a list of clinical trials in this disease area, please click here.